Treatment-Resistant Depression · Hayward, CA
TMS and SPRAVATO can sometimes belong in the same broader treatment plan for severe treatment-resistant depression. That does not mean they should automatically be done on the same day, or stacked together without a clear reason. For many patients, it makes more sense to use them sequentially, or with careful overlap. The goal is to know what is helping, what is causing side effects, and whether the schedule is realistic enough to complete safely.
How the treatments are different
TMS is a non-medication treatment that uses magnetic pulses to stimulate brain circuits involved in mood. Traditional TMS for depression usually requires a serious schedule commitment, often daily sessions over several weeks.[2][3]
SPRAVATO is esketamine nasal spray. It is FDA-approved for adults with treatment-resistant depression and is given in a monitored clinic setting. After each session, patients are watched for side effects such as sedation, dissociation, blood pressure changes, dizziness, or anxiety.[1] Patients also need transportation home after SPRAVATO and should not drive or do activities requiring full alertness until the next day after restful sleep, according to the prescribing information.[1]
They don’t overlap pharmacologically.
Magnetic circuit stimulation
No drug enters the body. Magnetic pulses stimulate the mood-related circuits of the brain from the outside, over repeated sessions.
Glutamate / esketamine
A medication you receive. Esketamine acts on glutamate signaling — a different biological pathway — under clinic monitoring.
Why “both” is not always better at the same time
Doing TMS and SPRAVATO too close together can make the treatment harder to read. If depression improves, it may be unclear which treatment helped. If anxiety, irritability, insomnia, dissociation, blood pressure changes, or emotional instability appears, it may be harder to know what caused it.
That matters because severe depression treatment needs clear information.[4] A good plan should not simply add intensity. It should add clarity. Sometimes a provider may recommend finishing one treatment course first, then reassessing. Sometimes a patient may start one treatment and add the other later if improvement is partial. In some cases there may be overlap, but it should be intentional and closely monitored.
What safe combined or sequential use requires.
- Provider coordination — one clinical picture, one team deciding why each treatment is in the plan.
- Monitoring — watching for what each treatment causes, from dissociation and blood pressure changes to anxiety, insomnia, or mood shifts.
- Schedule realism — frequent TMS sessions plus monitored SPRAVATO visits have to fit a life you can actually keep up with.
- Individualized sequencing — finish one course first, add the other for partial response, or overlap intentionally — chosen for you, not by default.
What a provider should consider
A careful consult should look at how severe the depression is now, whether there is partial response to one treatment already, and whether anxiety, panic, or dissociation sensitivity is present. It should also weigh whether the patient can manage the appointment schedule, and whether blood pressure, substance use, bipolar symptoms, trauma, or medical issues change the risk.[4] Insurance coverage for both treatments in the proposed sequence belongs in the conversation too.
The question is not, “Can we throw everything at the depression?” The better question is: what order of treatment gives this patient the best chance of improving safely?
The takeaway
TMS and SPRAVATO are not automatically either/or, and they are not automatically better together. They may both fit into a complex-care plan for treatment-resistant depression, but usually with sequencing, spacing, or careful overlap rather than being piled on top of each other. The goal is not to stack treatments for the sake of intensity. The goal is to build a plan that is strong, readable, and safe.
Wondering if both belong in your plan?
That’s a consult question, not a guess. We’ll look at how severe things are now, what’s already partly working, and what your schedule can carry — then decide whether to sequence, space, or carefully overlap.
References
- U.S. Food and Drug Administration. SPRAVATO (esketamine) nasal spray — Highlights of Prescribing Information. Revised 2025. accessdata.fda.gov (211243s019lbl.pdf). (J&J standalone monotherapy approval for treatment-resistant depression announced January 21, 2025.)
- Perera T, George MS, Grammer G, et al. The Clinical TMS Society consensus review and treatment recommendations for TMS therapy for major depressive disorder. Brain Stimul. 2016;9(3):336-346. PMID: 27090022 · doi:10.1016/j.brs.2016.03.010.
- McClintock SM, Reti IM, Carpenter LL, et al. Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. J Clin Psychiatry. 2018;79(1):16cs10905. PMID: 28541649 · doi:10.4088/JCP.16cs10905.
- McIntyre RS, Alsuwaidan M, Baune BT, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22(3):394-412. PMID: 37713549 · doi:10.1002/wps.21120.
Comments are closed